The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorization for the mRNA respiratory syncytial virus (RSV) vaccine mRESVIA (mRNA-1345) to protect adults aged 60 years or older from lower respiratory tract disease caused by RSV infection…
